VEGFR3/Flt-4 Antibody (LY3022856) - Low Endotoxin, Azide and BSA Free

• Reactivity: Hu
• Applications: ELISA, Flow, Func
• Clone: LY3022856
• Clonality: Monoclonal
• Host: Human
• Conjugate: Unconjugated
• Format: Low Endotoxin, Azide and BSA Free
• Concentration: LYOPH

VEGFR3/Flt-4 Antibody (LY3022856) - Low Endotoxin, Azide and BSA Free Summary

• Description: The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
  
  This product is shipped at ambient temperature. Upon receipt, store immediately at -20C or lower for 12 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.
  
  Patent #: US20130280278
• Additional Information: Recombinant Monoclonal Antibody
• Immunogen: VEGFR3 / FLT4
• Source: CHO
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Human
• Gene: FLT4
• Purity: Protein A purified
• Endotoxin Note: < 0.001EU/ug,determined by LAL method.

Applications/Dilutions

• Dilutions:
  • ELISA
  • Flow Cytometry
  • Functional

Packaging, Storage & Formulations

• Storage: Store at -20C in powder form. Store at -80C once reconstituted.
• Buffer: Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)
• Preservative: No Preservative
• Concentration: LYOPH
• Purity: Protein A purified
• Reconstitution Instructions: Reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

Alternate Names for VEGFR3/Flt-4 Antibody (LY3022856) - Low Endotoxin, Azide and BSA Free

• EC 2.7.10
• EC 2.7.10.1
• FLT4
• Flt-4
• fms-related tyrosine kinase 4
• LMPH1A
• PCLFLT41
• soluble VEGFR3 variant 1
• soluble VEGFR3 variant 2
• soluble VEGFR3 variant 3
• Tyrosine-protein kinase receptor FLT4
• vascular endothelial growth factor receptor 3
• VEGF R3
• VEGFR3
• VEGFR-3
• VEGFR3Fms-like tyrosine kinase 4

Background

FLT4, a VEGF Receptor type protein kinase, is an endothelial cell-specific receptor. Binding of the extracellular domain of FLT4 to the vascular endothelial growth factor-related protein VEGF-C stimulates tyrosine phosphorylation and mitogenesis of endothelial cells. FLT4 (-/-) mice have been shown to have defective blood vessel development in early embryos and to experience cardiovascular failure at embryonic day 9.5. A mutation in the FLT4 gene has been implicated in human hereditary lymphedema type I. Similarly, a mutation in the conserved catalytic domain of FLT4, in close proximity to the FLT4 mutations in human primary lymphedema, has been linked to the Chy mouse mutant.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: FLT4
• Uniprot:
  • P35916()